Vijay Kedia paid Rs. 12.5 crore block deal to buy 9 lakh shares of SME stock Mahamaya Lifesciences

Vijay Kedia paid Rs. 12.5 crore block deal to buy 9 lakh shares of SME stock Mahamaya Lifesciences

Ace investor Vijay Kedia bought nearly 9 lakh shares in SME stock Mahamaya Lifesciences through a block deal on Tuesday. This share is Rs. 140 were purchased, giving a transaction value of Rs. 12.48 crores.

Kedia through its investment company Kedia Securities Pvt Ltd. per share Rs. The shares were bought at a 2.8% discount from Monday’s closing price of 144.05.

Listed on November 18, 2025, shares of Mahamaya Lifesciences traded today on BSE at Rs. reached an all-time high of 161.70.

The stock also saw another block deal where Almondz Global Securities Limited traded at Rs. 1.51 lakh shares were sold at a price of 143.64.

Mahamaya Lifesciences is a manufacturer and exporter of pesticide formulations and crop protection products listed on the BSE SME platform.

Listing of shares at Rs. 116 per share at Rs. 114 against the issue price. But the stock has extended its lead since its market debut. It is now 42% higher than the IPO price.

Also Read: Ola Electric Bulk Deal: Promoter Bhavish Agarwal Gets Rs. Sold 2.6 crore shares worth Rs 92 crore

Rs. 70.44 crore in the IPO at Rs. 64.28 crore of new issue and Rs. 6.16 crores including an offer to sell.

The IPO was oversubscribed 1.63 times overall, led by strong NII participation of 3.63 times, while the retail category ended at 1.02 times – just above full subscription. QIBs bid 1.19 times, reflecting the measured institutional trend. A higher minimum investment size of the issue for retail investors is Rs. 2,73,600 also means limited participation of small applicants.

Mahamaya Lifesciences manufactures pesticide formulations, technical-grade molecules and branded agri-inputs. It supplies bulk products to local agrochemical companies and several multinational companies.

The company also has a global footprint with product registration and sales in countries including Egypt, Ethiopia, Jordan, UAE and Turkey. Its product portfolio spans key formulations such as acetamiprid, emamectin benzoate, imidacloprid, paraquat dichloride and multiple branded plant-health products.

The company reported strong growth in FY25, with revenue up 64% to Rs. 267.17 crore, while PAT increased by 148% to Rs. 12.94 crores. EBITDA increased to Rs. 24.64 crore and the net worth almost doubled to Rs. 49.42 crores.

The proceeds of the IPO will be used for purchase of equipment, setting up of new technical manufacturing plants, warehouse construction, working capital requirements and general corporate purposes.

Also Read: Usha Martin Block Deal: Promoter Entity Rs. 99 crores shares are sold. Morgan Stanley among the buyers

(Disclaimer: Recommendations, suggestions, opinions and views given by experts are their own. These do not represent the views of Economic Times.)

Add ET logo As a trusted and reliable news source
Google logo Add now!


(You can now subscribe to our ETMarkets WhatsApp channel)

Zeen Subscribe
A customizable subscription slide-in box to promote your newsletter
[mc4wp_form id="314"]